NO965160L - New farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing the compounds - Google Patents
New farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing the compoundsInfo
- Publication number
- NO965160L NO965160L NO965160A NO965160A NO965160L NO 965160 L NO965160 L NO 965160L NO 965160 A NO965160 A NO 965160A NO 965160 A NO965160 A NO 965160A NO 965160 L NO965160 L NO 965160L
- Authority
- NO
- Norway
- Prior art keywords
- radical
- alkyl
- optionally substituted
- general formula
- carbon atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Abstract
Novel farnesyl transferase inhibitors of general formula (I), their preparation and pharmaceutical compositions containing same. In general formula (I), R1 is Y-S-A1 -(Y is a hydrogen atom, an amino acid residue, a fatty acid residue, an alkyl or alkoxycarbonyl radical or an R4-S radical in which R4 is an alkyl radical containing 1-4 carbon atoms optionally substituted by a phenyl radical or a radical of general formula (II), in which A1, X1, Y1, R'1, R2, R'2 and R are defined as follows: A1 is an alkylene radical containing 1-4 carbon atoms optionally a substituted at alpha in the grouping >C(X1)(Y1) with an amino or alkylamino, dialkylamino, alkanylamino or alkoxycarbonylamino radical), X1 and Y1 are each a hydrogen atom or form together with the carbon atom to which they are connected a >C=O grouping, R'1 is hydrogène or methyl, R2 is an alkyl, alkenyl or alkynyl radical containing 1-6 carbon atoms optionally substituted by hydroxy, alkoxy, mercapto, alkylthio, alkylsulfinyl or alkylsulfonyl, with the proviso that when R2 is an alkyl radical substituted by a hydroxy radical, R2 can form a lactone with the carboxy radical at alpha . R'2 is hydrogen or methyl and R is a hydrogen atom or an optionally substituted alkyl radical or an optionally substituted phenyl radical, whith the proviso that the radical (a) is in position 5 or 6 of the naphthyl ring. These novel products have anti-cancer properties.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9407116A FR2721021B1 (en) | 1994-06-10 | 1994-06-10 | New farnesyl transferase inhibitors, their preparation and the pharmaceutical compositions containing them. |
FR9412338A FR2725717B1 (en) | 1994-10-17 | 1994-10-17 | NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
PCT/FR1995/000739 WO1995034535A1 (en) | 1994-06-10 | 1995-06-07 | Novel farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing same |
Publications (2)
Publication Number | Publication Date |
---|---|
NO965160L true NO965160L (en) | 1996-12-03 |
NO965160D0 NO965160D0 (en) | 1996-12-03 |
Family
ID=26231226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO965160A NO965160D0 (en) | 1994-06-10 | 1996-12-03 | New farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing the compounds |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0764149B1 (en) |
JP (1) | JPH10501259A (en) |
CN (1) | CN1150419A (en) |
AT (1) | ATE175958T1 (en) |
AU (1) | AU2742195A (en) |
BR (1) | BR9508187A (en) |
CA (1) | CA2192389A1 (en) |
CZ (1) | CZ361996A3 (en) |
DE (1) | DE69507476D1 (en) |
FI (1) | FI964920A0 (en) |
NO (1) | NO965160D0 (en) |
PL (1) | PL317580A1 (en) |
SK (1) | SK158196A3 (en) |
TW (1) | TW365602B (en) |
WO (1) | WO1995034535A1 (en) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6265603B1 (en) | 1997-02-27 | 2001-07-24 | Eisai Co., Ltd. | Inhibitors of isoprenyl transferase |
GB2323842A (en) * | 1997-04-04 | 1998-10-07 | Ferring Bv | Pyridine derivatives |
GB2323841A (en) * | 1997-04-04 | 1998-10-07 | Ferring Bv Group Holdings | Pyridine derivatives with anti-tumor and anti-inflammatory activity |
US6071547A (en) * | 1998-10-08 | 2000-06-06 | Superior Nutrition Corporation | Textured dry mix instant nutritional drink |
US6486202B1 (en) | 2001-04-13 | 2002-11-26 | Eisai Company, Limited | Inhibitors of isoprenyl transferase |
US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
SI2010528T1 (en) | 2006-04-19 | 2018-02-28 | Novartis Ag | 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling |
WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
PL2336120T3 (en) | 2007-01-10 | 2014-12-31 | Msd Italia Srl | Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
MX2009009304A (en) | 2007-03-01 | 2009-11-18 | Novartis Ag | Pim kinase inhibitors and methods of their use. |
CA2685967A1 (en) | 2007-05-21 | 2008-11-21 | Novartis Ag | Csf-1r inhibitors, compositions, and methods of use |
CA2690191C (en) | 2007-06-27 | 2015-07-28 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
PE20121172A1 (en) | 2009-10-14 | 2012-09-05 | Merck Sharp & Dohme | PIPERIDINS SUBSTITUTED WITH ACTIVITY IN HDM2 |
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
BR112012023021A2 (en) | 2010-03-16 | 2016-05-31 | Dana Farber Cancer Inst Inc | indazole compounds and their uses |
US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
CA2805265A1 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
CA2807307C (en) | 2010-08-17 | 2021-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
EP2632472B1 (en) | 2010-10-29 | 2017-12-13 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
IN2013MN02170A (en) | 2011-04-21 | 2015-06-12 | Piramal Entpr Ltd | |
WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
EP3569598A1 (en) | 2011-11-17 | 2019-11-20 | Dana Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
EP2844261B1 (en) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
WO2014052563A2 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
MX363243B (en) | 2012-11-28 | 2019-03-14 | Merck Sharp & Dohme | Compositions and methods for treating cancer. |
BR112015013611A2 (en) | 2012-12-20 | 2017-11-14 | Merck Sharp & Dohme | compound and pharmaceutical composition |
EP2951180B1 (en) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
AU2014337044A1 (en) | 2013-10-18 | 2016-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
ES2676734T3 (en) | 2013-10-18 | 2018-07-24 | Syros Pharmaceuticals, Inc. | Heteroatomic compounds useful for the treatment of proliferative diseases |
CN105849087A (en) | 2013-12-27 | 2016-08-10 | 诺华丝国际股份有限公司 | Ethoxylated surfactants |
WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
JO3589B1 (en) | 2014-08-06 | 2020-07-05 | Novartis Ag | Protein kinase c inhibitors and methods of their use |
JP6854762B2 (en) | 2014-12-23 | 2021-04-07 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Inhibitor of cyclin-dependent kinase 7 (CDK7) |
JP6861166B2 (en) | 2015-03-27 | 2021-04-21 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Inhibitor of cyclin-dependent kinase |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
CA2996978A1 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
WO2017162122A1 (en) * | 2016-03-23 | 2017-09-28 | Yu-Jen Chen | Farnesyl transferase inhibitors and uses thereof |
JOP20190055A1 (en) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | Anti-cd27 antibodies |
MX2019012233A (en) | 2017-04-13 | 2020-01-14 | Aduro Biotech Holdings Europe Bv | Anti-sirp alpha antibodies. |
US10584306B2 (en) | 2017-08-11 | 2020-03-10 | Board Of Regents Of The University Of Oklahoma | Surfactant microemulsions |
WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
US20210277009A1 (en) | 2018-08-07 | 2021-09-09 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2044333A1 (en) * | 1990-06-12 | 1991-12-13 | Jackson B. Gibbs | Chemotherapeutic agents |
US5352705A (en) * | 1992-06-26 | 1994-10-04 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
US5504212A (en) * | 1992-10-29 | 1996-04-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
-
1995
- 1995-06-07 BR BR9508187A patent/BR9508187A/en not_active Application Discontinuation
- 1995-06-07 TW TW084105739A patent/TW365602B/en active
- 1995-06-07 CN CN95193511A patent/CN1150419A/en active Pending
- 1995-06-07 EP EP95922573A patent/EP0764149B1/en not_active Expired - Lifetime
- 1995-06-07 DE DE69507476T patent/DE69507476D1/en not_active Expired - Lifetime
- 1995-06-07 CZ CZ963619A patent/CZ361996A3/en unknown
- 1995-06-07 SK SK1581-96A patent/SK158196A3/en unknown
- 1995-06-07 CA CA002192389A patent/CA2192389A1/en not_active Abandoned
- 1995-06-07 WO PCT/FR1995/000739 patent/WO1995034535A1/en not_active Application Discontinuation
- 1995-06-07 AU AU27421/95A patent/AU2742195A/en not_active Abandoned
- 1995-06-07 JP JP8501714A patent/JPH10501259A/en active Pending
- 1995-06-07 AT AT95922573T patent/ATE175958T1/en not_active IP Right Cessation
- 1995-06-07 PL PL95317580A patent/PL317580A1/en unknown
-
1996
- 1996-12-03 NO NO965160A patent/NO965160D0/en unknown
- 1996-12-09 FI FI964920A patent/FI964920A0/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
SK158196A3 (en) | 1997-07-09 |
CA2192389A1 (en) | 1995-12-21 |
DE69507476D1 (en) | 1999-03-04 |
EP0764149B1 (en) | 1999-01-20 |
AU2742195A (en) | 1996-01-05 |
FI964920A (en) | 1996-12-09 |
FI964920A0 (en) | 1996-12-09 |
TW365602B (en) | 1999-08-01 |
BR9508187A (en) | 1997-08-12 |
ATE175958T1 (en) | 1999-02-15 |
JPH10501259A (en) | 1998-02-03 |
CN1150419A (en) | 1997-05-21 |
EP0764149A1 (en) | 1997-03-26 |
NO965160D0 (en) | 1996-12-03 |
WO1995034535A1 (en) | 1995-12-21 |
PL317580A1 (en) | 1997-04-14 |
CZ361996A3 (en) | 1997-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO965160L (en) | New farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing the compounds | |
NO973222L (en) | New farnesyl transferase inhibitors, their preparation and pharmaceutical preparations containing the inhibitors | |
ATE242231T1 (en) | CARBONYL-PIPERAZNYL AND PIPERIDINYL DERIVATIVES FOR INHIBITING FARNESYL PROTEIN TRANSFERASE | |
KR950032114A (en) | Proline amide derivative | |
ES2137169T3 (en) | NEW DERIVATIVES OF TIAZOLILBENZOFURANO, PROCEDURES FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM. | |
NO973608L (en) | New farnesyl transferase inhibitors, their preparation and pharmaceutical preparations containing the compounds | |
CA2304713A1 (en) | Biphenyl-5-alkanoic acid derivatives and use thereof | |
NO973607L (en) | New farnesyl transferase inhibitors, their preparation and preparations containing the inhibitors | |
ES8301925A1 (en) | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids, salts thereof, pharmaceutical compositions containing the derivatives or salts, and the production of the same. | |
WO2004071388A3 (en) | Medicinal compounds | |
DE69230958T2 (en) | Medicinal composition based on dioxabicyclo [3.3.0] octane derivatives | |
GB9308487D0 (en) | Novel compounds | |
GR3001879T3 (en) | Cytoprotective derivatives useful in ischemic diseases, their preparation and compositions containing them | |
ES8507090A1 (en) | 1,5-Benzothiazepines with cardiovascular utility, and pharmaceutical compositions containing them | |
TW200508274A (en) | Antioxidant and bisaminophenol derivative | |
HUP0303279A2 (en) | Indolylopyrrolocarbazoles sugar derivatives as topoisomerase inhibitors and pharmaceutical compositions containing them | |
CA2127067A1 (en) | Phosphonic Acid Derivatives, Their Preparation Process and Pharmaceutical Compositions Containing Them | |
MX9606106A (en) | Novel farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing same. | |
CY1106058T1 (en) | STABLE COMPOSITIONS OF OXAPENEM-3-CARBOXYLIC ACIDS CO-LYOPHILOZING WITH PHARMACEUTICAL CARRIERS | |
EA200300029A1 (en) | NEW CARBAMAT COMPOUNDS AND PODOPHILLOTOXIN THIOCARBAMAT, METHOD FOR THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS | |
SE9701912D0 (en) | Pharmaceutical composition and use thereof | |
DE69822167D1 (en) | ANTIMICROBIAL CONNECTIONS | |
ES2023760A6 (en) | Benzothiazine derivatives, their preparation and their uses as medicines or as intermediates for the synthesis of medicines. | |
WO2004094396A3 (en) | Dihydrothiazine prodrugs of thiazolium agents | |
MY142362A (en) | Pharmaceutical composition for promoting angiogenesis |